Skip to search formSkip to main contentSkip to account menu

Olmesartan medoxomil

Known as: 1H-Imidazole-5-carboxylic Acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester, 5-Methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate - T287346, Olmesartan Medoxomil [Chemical/Ingredient] 
A synthetic imidazole derivative prodrug with an antihypertensive property. Upon hydrolysis, olmesartan medoxomil is converted to olmesartan… 
National Institutes of Health

Related topics

Related topics

30 relations
Amlodipine 10 MG / Hydrochlorothiazide 25 MG / Olmesartan medoxomil 40 MG Oral TabletAmlodipine 10 MG / Hydrochlorothiazide 25 MG / Olmesartan medoxomil 40 MG Oral Tablet [Tribenzor]Amlodipine 5 MG / Olmesartan medoxomil 40 MG Oral Tablet [Azor]Angiotensin 2 Receptor Antagonists [MoA]

Broader (3)

Angiotensin II Type 1 Receptor BlockersAntihypertensive Agentsolmesartan

Narrower (5)

AzorBenicarCS 866Tribenzor

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil employing multivariate statistical techniques
Abstract Purpose: This research work entails quality by design (QbD)-based systematic development of nanostructured lipid… 
Highly Cited
2018
Highly Cited
2018
Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation
Abstract The aim was to enhance the oral bioavailability of olmesartan medoxomil (OM) by preparing solid lipid nanoparticles… 
Highly Cited
2017
Highly Cited
2017
Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability.
Highly Cited
2014
Highly Cited
2014
Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats.
Highly Cited
2012
Highly Cited
2012
Development of a novel 96-microwell assay with high throughput for determination of olmesartan medoxomil in its tablets
A novel 96-microwell-based spectrophotometric assay has been developed and validated for determination of olmesartan medoxomil… 
Highly Cited
2011
Highly Cited
2011
Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension
Azilsartan medoxomil is an angiotensin receptor blocker (ARB) being developed for hypertension treatment. To compare this ARB… 
Highly Cited
2010
Highly Cited
2010
Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF)-Trial Running title: Goette et al.; The ANTIPAF Trial
University Hospital Magdeburg, Magdeburg; Dept of Cardiology & Intensive Care Med, St. Vincenz-Hospital Paderborn, Paderborn… 
2009
2009
Solubilized formulation of olmesartan medoxomil for enhancing oral bioavailability
Olmesartan medoxomil (OLM) is an antihypertensive angiotensin II receptor blocker. OLM has a low bioavailability (BA… 
Highly Cited
2009
Highly Cited
2009
Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension.
AIM Recently, a novel device for measuring the cardio-ankle vascular index (CAVI) as an arterial stiffness parameter has been… 
Review
2002
Review
2002
Use of angiotensin II receptor blockers in animal models of atherosclerosis.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)